Condition: Relapsed or Refractory Non-Hodgkin's Lymphoma · Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.
This description comes directly from the study's public registry record.
Xiaoyan Lou, Dr. · 18721281671 · xiaoyan.lou@unicar-therapy.com
Liqing Kang, Dr. · 13162512992 · liqing.kang@unicar-therapy.com
Always discuss trial participation with your own doctor first.
| The Third Xiangya Hospital of Central South University | Changsha, Hunan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05768529